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Chemotherapyd immortalisation (telomerase) have been linked to the root of cancer. In glioma,
MGMT expression is negatively regulated through promoter methylation and its absence is associated with
enhanced chemosensitivity. However, recent studies indicate that telomerase is positively regulated through
methylation and its elimination enhances chemotherapy. These observations suggest that suppression of
telomerase in combination with MGMT may have additional anti-proliferative and anti-apoptotic effects,
which may lead to increased patient survival rates. However, different approaches may be required to
compliment the epigenetic events that regulate these genes. Nevertheless, given that median survival of
glioma patients is less than a year, this review focuses on the recent approaches used to target MGMT and
telomerase, with a view to increase life expectancy of patients while limiting side effects.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Glioma is the most malignant form of brain tumour, with median
survival rate of less thanayear [1] and thus consequentlyassociatedwith
the worst prognosis. Malignant gliomas are notoriously resistant to
many of the currently available therapies such as cisplatin, carmsutine
(BCNU), lomustine (CCNU), vincristine (PCV) and temozolomide (TMZ)
because these cancer cells cannot be induced to undergo apoptosis upon
anticancer treatment [2,3]. Furthermore, gliomas almost always grow
back even after complete surgical excision [4].
Gliomas can occur either spontaneously termed de novo (primary),
or through malignant progression from a lower-grade lesion (sec-
ondary). Secondary gliomas tend to develop in younger patients in
comparison to primary, through malignant progression from diffuse
astrocytomas or anaplastic astrocytomas. The median survival rate of
secondary glioma patients (7.8 months) is signiﬁcantly longer than
that of primary glioma patients (4.7 months), largely due to the
younger age of secondary glioma patients in general [5]. The complex
mutational pathways leading to primary or secondary gliomas entail
different gene mutations, deletions, and ampliﬁcations (Fig. 1) [6,7].
However this reviewwill focus on the role of O6 methylguanine-DNA-
methyltransferase (MGMT) and telomerase in glioma.
2. MGMT regulation in glioma
MGMT also known as O6 alkylguanine-DNA-alkyltransferase, is a
DNA repair gene that has been studied extensively in glioma. With its
potential to increase anticancer efﬁcacy of many alkylating agents44 1772894981.
ington).
ll rights reserved.MGMT inhibition is now at the forefront of glioma research. Most DNA
repair enzymes are responsible for repairing double or single strand
breaks, neverthelessmethylation of cytosine residues that proceed the
guanine (G) residues, i.e. methylation of CpG (cytidine-phosphate-
guanosine) dinucleotides are not excision of double or single DNA
strands [10]. Methylation of cytosine is the normal way in which cells
regulate gene expression, however, methylation of CpG dinucleotides
leads to mispairing during DNA replication and is the by-product of
DNA damage. MGMT transfers the alkyl/methyl groups to its active
cysteine residue in a stoichiometric and autoinactivating process
requiring resynthesis (suicidal repair enzyme) [11] thereby, averting
the formation of lethal cross-links. One MGMTmolecule is inactivated
for each lesion repaired, thusMGMT itself is consumed due to its rapid
degradation through the ubiquitin–proteasome pathway after receiv-
ing alkyl groups from DNA [12]. Furthermore, repletion of the cellular
MGMT pool depends on the re-synthesis of the molecule. O6-guanine
lesions are produced by carcinogenic methylating alkylating agents
used in therapy [13]. Thus, the repair of all O6-alkyl/methyl-guanine-
DNA lesions is essential for cell integrity and if un-repaired can result
in mutagenesis.
The crystal structure of the MGMT protein shows that the transfer
reaction takes place through the localisation of guanine in the MGMT
pocket by the local amino acid side chain [14,15]. To initiate repair, it
binds DNA and scans individual bases for evidence of DNA adducts
[16]. MGMT directly removes DNA modiﬁcations from the O6 atom of
guanine such as O6-ethylguanine (O6-EG), which is formed by
ethylnitrosourea, and diethylnitrosamine and related compounds
including chloroethyl, pyridyloxobutyl, butyl and benzyl adducts
[14]. Unlike all other repair enzymes that work together forming
multi-enzyme complexes to initiate and remove abnormalities within
DNA [17], MGMT, exclusively works alone to repair DNA adducts. Thus,
implying that the MGMT repair reaction is remarkably simple and
Fig. 1. Genetic pathways in the evolution of primary and secondary gliomas (adapted and revised from [7–9]).
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methylation [18]. FurthermoreMGMT is amonomer that can act in the
absence of cofactors and energy sources and is instrumental in DNA
repair (Fig. 2).
Numerous brain tumours exhibit loss of heterozygosity (LOH) of
chromosome 10, with MGMT located at 10q26 may subsequently be
lost therefore the majority of gliomas only have one copy of theMGMT
gene [19]. Deﬁciency of MGMT was shown to increase the chemo-
sensitivity of the alkylating agents in brain tumours. Although in
gliomas, MGMT is sometimes mutated or deleted, the major loss of
MGMT gene expression is often a result of CpG island hypermethyla-Fig. 2.MGMTat work. MGMT scans double-stranded DNA for alkylation at the O6 position of
restoring the guanine to normal (adapted from [14]).tion [10] commonly seen in solid tumours, speciﬁcally gliomas [20].
The predictive value of MGMT promoter methylation was tested in
glioma patients treated with temozolomide (TMZ), this showed that
promoter methylationwas a surrogatemarker for response to therapy.
Patients with a methylated MGMT promoter survive up to 30 months
longer than those without [17]. However, loss of MGMT increases the
risk of mutations and malignant transformation, suggesting that
MGMT promoter methylation is an important epigenetic event in
tumourgenesis itself. MGMT protein plays a pivotal role in cellular
defence against alkylating agents and thus its quantiﬁcation may be
important both as a biomarker and for drug sensitivity testing [21].guanine and covalently transfers it to its active-site cysteine, inactivating the MGMTand
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MGMT repression has been associated with increase overall
survival rates. 60% of glioma patients with an inactivated MGMT
demonstrated a partial or complete response to drug therapy,
compared with only 4% of those with intact MGMT capability [17].
Methylation of the MGMT promoter is associated with better
responsiveness to carmustine and increased overall survival, which
is a better predictor of the outcome, than the grade of the tumour [11].
However, no correlation has been found to determine a link between
promoter hypermethylation and MGMT protein expression in oligo-
dendrogliomas [22]. The success of MGMT depletion as a strategy for
therapy depends upon O6-alkylation being the determinant of cancer
cell death [23] and whether the tumour cell expresses MGMT in the
ﬁrst instance (Fig.1). A greater proportion of secondary gliomas have a
methylated MGMT promoter in contrast to primary gliomas, therefore
secondary glioma patients should be more respondent to alkylating
agents. Nevertheless, this increase in chemosensitivity should bemore
preferential in oligodendrogliomas which have the highest rate of
MGMT methylation rates [7].
Researchers have developed O6-benzylguanine (BzG), O6-4-bro-
mothenylguanine (Patrin) and O6-bromothenylguanine-C8-β-D-glu-
coside [24] as alternative substrates of MGMT, which irreversibly
inactivates the MGMT protein and thereby potentiates the effect of
alkylating agents such as TMZ and the nitrosoureas to improve.
Although, BzG and Patrin have gone through phase I and II clinical
trials [25], the suboptimal nature of their pharmaceutical and
pharmacokinetic properties suggests that other MGMT inhibitors
(BzG analogues) may be required for the true potential of MGMT
modulation [21,26]. More recently Hegi et al. reviewed the data
supporting MGMT as a major mechanism of chemotherapy resistance
(speciﬁcally TMZ) inmalignant gliomas and found that somemethods
of inhibiting MGMT would beneﬁt patients with an unmethylated
MGMT promoter, albeit this may not guarantee success [27].
Furthermore, not all MGMT negative tumour patients show response
to therapy thus further work underpinning resistance-modulating
mechanisms may be a necessity for the future.
While increasing evidence shows that TMZ, the most efﬁcacious
treatment, is the way forward with regard to glioma therapy, a
reliable and routine method of determining MGMT status in patients
is required to enhance survival outcome. Additionally, treatment that
caters for patients with either positive or negative MGMT expression
would be the way forward for glioma treatment. Recent data from
our laboratory involving the combination of 5-Aza-2′-deoxycytidine
(5azadC) and paxitaxol as a treatment showed reduced cell viability
by two fold of two glioma cell lines, suggesting an alternative
method of targeting gliomas that do not rely on TMZ [28]. Greater
than 30–50% of glioma patients have an unmethylated MGMT
promoter, thus increasing the need for a new therapy approach
that does not rely on alkylating agents. Careful tailored treatment
dependant on MGMT proﬁle, utilizing RT-PCR analysis directly
following tumour tissue removal had led to a 71% two year survival
rate of glioma patients [29]. This by far exceeds the general survival
rate of glioma patients. However, careful consideration must be
taken to assess only the tumour region of the brain as the non-
neoplastic brain components such as lymphocytes, vascular endothe-
lial cells, and macrophages/microglias, may contribute to the overall
MGMT expression detected in tumour homogenates resulting in
overestimation of tumour MGMT expression [30] leading to
misjudgement of treatment.
4. Telomerase activity in malignant gliomas
Nevertheless, according to the literature many other genes are
activated/silenced to maintain tumour development and progression.
These include genes to promote angiogenesis, (growth of new bloodvessels to support new tumour tissue), genes to promote mobility
(cancer can spread) and genes to “immortalise” (allow cells to
proliferate indeﬁnitely, without replicative senescence) [31]. The
ability of cancer cells to become immortal is one of the main
characteristics that distinguish them from their normal counterparts.
To escape replicative senescence important cell cycle genes are lost or
activated which include p53, p21, p16INK4a, Rb and telomerase [32].
The complex transcriptional regulation of telomerase with its
intercalating pathways, has led us to evaluate its epigenetic regula-
tion, through the methylation status of the hTERT gene. Given that
immortalisation not only requires telomerase but needs imbalance/
inactivation of DNA repair functions, further supports the need to
understand MGMT and telomerase interactions through promoter
methylation. Most genes are switched off when the promoter is
methylated, in contrast, hTERT (telomerase active subunit) expression
in some tissues (colerectral, ovarian and cervical cancer) seems to
undermine this general rule and positive correlations between
hypermethylation of the hTERT promoter, hTERT mRNA expression
and telomerase activity have been reported [33,34]. Moreover,
mammalian telomeres have enriched epigenetic regions, without
which regulation of telomerase would be uncontrollable [35,36] thus
enhancing evidence for epigenetic regulation controlling the expres-
sion of telomerase in general.
Researchers have studied telomerase in glioma over 10 years with
the earliest reported study in 1995 which assessed telomerase
activity as a marker for malignancy [37]. The study showed a
signiﬁcant correlation between pathological diagnosis and telomer-
ase, while 75% of gliomas have detectable telomerase activity, only
10% of the anaplastic astrocytomas have been found to be telomerase
positive [37–39]. Another report showed that the level of telomerase
activity and hTERT expression is signiﬁcantly higher in secondary
gliomas in comparison with primary and is correlated with p53
mutations during the early stage of carcinogenesis [40] thus
conﬁrming that senescence activated by p53 is due to telomere
dysfunction [41,42]. Moreover, low expression levels of telomerase
predicted better survival and correlated positively to the prognosis
and treatment not only in glioma's, but also in genitourinary and
colorectal cancers [1,43,44].
5. Targeting telomerase
There are currently a number of techniques used to target
telomerase, these include 2–5 antisense systems, viral constructs
expressing antisense transcripts, hammerhead ribozymes, peptide
nucleic acids (PNAs) dominant negative hTERT, immunotherapy and
reverse transcriptase inhibitors [45–47]. Although, various transla-
tional approaches have been adopted to target telomerase, some of
which are in the ﬁnal stages of preclinical development and others
currently in clinical trials, telomelysin trials have recently been
accessible for various solid tumours with no reference to gliomas [47].
Human glioma cell lines (T98G, LN-229, LN-18, U87MG and LN-
308) were subjected to penclomedine, an alkylating agent previously
reported to inhibit telomerase activity in human cervical carcinoma
cells, found that telomerase activity was unaffected [48], concluding
that telomerase activity may not be a suitable target to enhance
chemosensitivity of malignant gliomas given its complex regulation.
Furthermore, quantiﬁcation of telomerase in brain tumours showed
that there was no correlation between downregulation of telomerase
and patient survival [49]. These differences may be due to the
methods used in analysing telomerase or a genuine difference in the
expression. However, this ﬁnding was not in agreement with a study
in 2006 which showed that median survival time of patients with
and without telomerase activity were 21 and 34 months respectively,
indicating that telomerase activity is an important prognostic
factor in predicting progression and survival of patients with brain
tumours [50]. Glioma cells sensitive to low doses of cisplatin died as
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to the success of cisplatin as an anticancer agent speciﬁcally for
glioma [51,52].
Vaccination with pseudotype baculovirus expressing hTERT in
animals with brain tumours induced protective anti-tumour immu-
nity to hTERT [53]. The level of hTERT transcript appeared to predict
survival in glioma patients (low hTERT expression, better survival)
[54]; therefore the development of anti-telomerase treatment for
malignant gliomas and hTERT analysis is essential. Intravenous
injections of hTERT-Ad suppressed the growth of subcutaneous
tumours in nude mice and prolonged the survival of mice with
gliomas, and the transfected cells underwent autophagic cell death via
inhibition of the mTOR signalling in telomerase positive tumours [55].
Telomerase itself plays an additional role in protecting chromosomes
by regulating the overall conﬁguration of the chromatin state and its
depletion affects chromatin structure and impairs activation of DNA
damage responses [56]. The signiﬁcant role of telomerase in glioma
pathogenicity can be a potential therapeutic target for gliomas.
Until recently it was unknown whether hTERT expression in
gliomaswas regulated via hypo or hypermethylation, in addition, data
regarding demethylation treatment assessing the expression of hTERT
was limited. Many drugs have been used to down regulate telomerase
methylation. Recently 5azadC treatment in glioma cell lines reduced
telomerase expression and activity, however given the complex
regulation of telomerase it was not clear by what mechanism this
was happening [28].
Indirect evidence showed that promoter methylation may be
inhibiting telomerase expression in glioma cells, thus by inhibiting the
methyltransferase gene DNMT1 using targeted siRNA, it was clearly
demonstrated that not only was the DNMT1 expression reduced, as a
knock on effect telomerase expressionwas also reduced. Furthermore
combining DNMT1 siRNA and chemotherapeutic drugs (taxol and
TMZ) enhanced the efﬁciency of the drug by up 7 and 4 fold,
respectively in glioma cells [57]. This in itself proposes that inhibition
of telomerase can be used to complement a direct cytotoxic agent,
possibly offering an alternative treatment by the use of lower
concentrations of the drug, hence reducing side effects and improving
the life expectancy of patients. However, its clinical implications will
require further elucidation of these ﬁndings with regard to tumour
grade and response. Inhibition of telomerase whether by means of
gene knockdown, chemical interactions or via immuno therapy, has
the potential to increase the efﬁciency of many anticancer agents such
as cisplatin, TMZ and PCVs, therefore it could be used in combination
therapies. The importance of studying telomeres in combination with
telomerase inhibition as a therapeutic target was shown to be a
prognostic tool in paediatric glioma patients [58].
6. Conclusion
Despite the technological advances in molecular biology that have
assisted in enhancing our understanding of cancer, there still remain
gaps in the our understanding of the mechanisms governing glioma.
Research directed towards gene therapy with particular focus on
telomerase andMGMTwill further aid development of new diagnostic
and therapeutic approaches to human gliomas. Given that malignant
gliomas are predominantly telomerase positive and normal somatic
cells are negative, targeting telomerase should fundamentally lead to
minimum side effects. Combining inhibition of both telomerase and
MGMT could further enhance glioma treatment and patient care.
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